Both low and high body mass index (BMI) have been associated with an increased risk of dementia, including that caused by Alzheimer’s disease (AD). Specifically, high middle-age BMI or a low late-age BMI has been considered a predictor for the development of AD dementia. Less studied is the relationship between BMI and AD pathology.
Objective:
We explored the association between BMI and cortical amyloid-β (Aβ) burden in cognitively normal participants that were either in mid-life (45–60 years) or late-life (>60).
Methods:
We analyzed cross-sectional baseline data from the Knight Alzheimer Disease Research Center (ADRC) at Washington University. Aβ pathology was measured in 373 individuals with Aβ PET imaging and was quantified using Centiloid units. We split the cohort into mid- and late-life groups for analyses (n = 96 and n = 277, respectively). We ran general linear regression models to predict Aβ levels from BMI while controlling for age, sex, years of education, and APOE4 status. Analyses were also conducted to test the interaction between BMI and APOE4 genotype and between BMI and sex.
Results:
Higher BMI was associated with lower cortical Aβ burden in late-life (β= –0.81, p = 0.0066), but no relationship was found in mid-life (β= 0.04, p > 0.5). The BMI×APOE4+ and BMI×male interaction terms were not significant in the mid-life (β= 0.28, p = 0.41; β= 0.64, p = 0.13) or the late-life (β= 0.17, p > 0.5; β= 0.50, p = 0.43) groups.
Conclusion:
Higher late-life BMI is associated with lower cortical Aβ burden in cognitively normal individuals.
WilsonRS, SegawaE, BoylePA, AnagnosSE, HizelLP, BennettDA (2012) The natural history of cognitive decline in Alzheimer’s disease. Psychol Aging27, 1008–1017.
2.
BarkerWW, LuisCA, KashubaA, LuisM, HarwoodDG, LoewensteinD, WatersC, JimisonP, ShepherdE, SevushS, Graff-RadfordN, NewlandD, ToddM, MillerB, GoldM, HeilmanK, DotyL, GoodmanI, RobinsonB, PearlG, DicksonD, DuaraR (2002) Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord16, 203–212.
3.
HebertLE, WeuveJ, ScherrPA, EvansDA (2013) Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology80, 1778–1783.
4.
U.S. Government Publishing Office, U.S. Census Bureau, International Population Reports, P95/16-1, An Aging World: 2015, Last updated 2016, Accessed on 2016.
5.
(2017) 2017 Alzheimer’s disease facts and figures. Alzheimers Dement13, 325–373.
6.
AghaM, AghaR (2017) The rising prevalence of obesity. Int J Surg Oncol2, e17.
7.
ZamboniM, MazzaliG, ZoicoE, HarrisTB, MeigsJB, Di FrancescoV, FantinF, BissoliL, BoselloO (2005) Health consequences of obesity in the elderly: A review of four unresolved questions. Int J Obes29, 1011–1029.
8.
StewartR, MasakiK, XueQ-L, PeilaR, PetrovitchH, WhiteLR, LaunerLJ (2005) A 32-year prospective study of change in body weight and incident dementia: The Honolulu-Asia Aging Study. Arch Neurol62, 55–60.
9.
LainscakM, von HaehlingS, DoehnerW, AnkerSD (2012) The obesity paradox in chronic disease: Facts and numbers. J Cachexia Sarcopenia Muscle3, 1–4.
FitzpatrickAL, KullerLH, LopezOL, DiehrP, O’MearaES, LongstrethWT, LuchsingerJA (2009) Midlife and late-life obesity and the risk of dementia. Arch Neurol66, 336–342.
12.
Singh-ManouxA, DugravotA, ShipleyM, BrunnerEJ, ElbazA, SabiaS, KivimakiM (2018) Obesity trajectories and risk of dementia: 28 years of follow-up in the Whitehall II Study. Alzheimers Dement14, 178–186.
MukherjeeS, WalterS, KauweJSK, SaykinAJ, BennettDA, LarsonEB, CranePK, GlymourMM, Adult Changes in Thought Study Investigators, Religious Orders Study/Memory and Aging Project Investigators, Alzheimer’s Disease Genetics Consortium (2015) Genetically predicted body mass index and Alzheimer’s disease-related phenotypes in three large samples: Mendelian randomization analyses. Alzheimers Dement11, 1439–1451.
15.
QizilbashN, GregsonJ, JohnsonME, PearceN, DouglasI, WingK, EvansSJW, PocockSJ (2015) BMI and risk of dementia in two million people over two decades: A retrospective cohort study. Lancet Diabetes Endocrinol3, 431–436.
AttiAR, PalmerK, VolpatoS, WinbladB, De RonchiD, FratiglioniL (2008) Late-life body mass index and dementia incidence: Nine-year follow-up data from the Kungsholmen Project. J Am Geriatr Soc56, 111–116.
19.
HughesTF, BorensteinAR, SchofieldE, WuY, LarsonEB (2009) Association between late-life body mass index and dementia: The Kame Project. Neurology72, 1741–1746.
20.
KuoH-K, JonesRN, MilbergWP, TennstedtS, TalbotL, MorrisJN, LipsitzLA (2006) Cognitive function in normal-weight, overweight, and obese older adults: An analysis of the advanced cognitive training for independent and vital elderly cohort. J Am Geriatr Soc54, 97–103.
21.
WhitmerRA, GundersonEP, Barrett-ConnorE, QuesenberryCP, YaffeK (2005) Obesity in middle age and future risk of dementia: A 27 year longitudinal population based study. BMJ330, 1360.
22.
GorospeEC, DaveJK (2006) The risk of dementia with increased body mass index. Age Ageing36, 23–29.
RosengrenA, SkoogI, GustafsonD, WilhelmsenL (2005) Body mass index, other cardiovascular risk factors, and hospitalization for dementia. Arch Intern Med165, 321–326.
25.
WhiteH, PieperC, SchmaderK (1998) The association of weight change in Alzheimer’s disease with severity of disease and mortality: A longitudinal analysis. J Am Geriatr Soc46, 1223–1227.
26.
AlbaneseE, TaylorC, SiervoM, StewartR, PrinceMJ, AcostaD (2013) Dementia severity and weight loss: A comparison across eight cohorts. The 10/66 study. Alzheimers Dement9, 649–656.
27.
BurnsJM, JohnsonDK, WattsA, SwerdlowRH, BrooksWM (2010) Reduced lean mass in early Alzheimer disease and its association with brain atrophy. Arch Neurol67, 428–343.
28.
WhiteH, PieperC, SchmaderK, FillenbaumG (1996) Weight change in Alzheimer’s disease. J Am Geriatr Soc44, 265–72.
29.
JohnsonDK, WilkinsCH, MorrisJC (2006) Accelerated weight loss may precede diagnosis in Alzheimer disease. Arch Neurol63, 1312–7.
30.
WhitwellJL, PrzybelskiSA, WeigandSD, KnopmanDS, BoeveBF, PetersenRCJr, CRJ (2007) 3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer’s disease. Brain130, 1777–1786.
31.
Barrett-ConnorE, EdelsteinSL, Corey-BloomJ, WiederholtWC (1996) Weight loss precedes dementia in community-dwelling older adults. J Am Geriatr Soc44, 1147–1152.
32.
BuchmanAS, WilsonRS, BieniasJL, ShahRC, EvansDA, BennettDA (2005) Change in body mass index and risk of incident Alzheimer disease. Neurology65, 892–897.
33.
ZhaoL, TeterB, MoriharaT, LimGP, AmbegaokarSS, UbedaOJ, FrautschySA, ColeGM (2004) Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: Implications for Alzheimer’s disease intervention. J Neurosci24, 11120–11126.
34.
HoL, QinW, PomplPN, XiangZ, WangJ, ZhaoZ, PengY, CambareriG, RocherA, Mobbs CV, HofPR, PasinettiGM (2004) Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer’s disease. FASEB J18, 902–904.
35.
FarrisW, MansourianS, ChangY, LindsleyL, Eckman Ea, FroschMP, EckmanCB, TanziRE, SelkoeDJ, GuenetteS (2003) Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain. Proc Natl Acad Sci U S A100, 4162–4167.
36.
McCleanPL, ParthsarathyV, FaivreE, HölscherC (2011) The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer’s disease. J Neurosci31, 6587–6594.
37.
LeissringMA, FarrisW, ChangAY, WalshDM, WuX, SunX, FroschMP, SelkoeDJ (2003) Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron40, 1087–1093.
38.
JolivaltCG, HurfordR, LeeCA, DumaopW, RockensteinE, MasliahE (2010) Type 1 diabetes exaggerates features of Alzheimer’s disease in APP transgenic mice. Exp Neurol223, 422–431.
39.
HsuDC, MorminoEC, SchultzAP, AmariglioRE, DonovanNJ, RentzDM, JohnsonKA, SperlingRA, MarshallGA (2016) Lower late-life body-mass index is associated with higher cortical amyloid burden in clinically normal elderly. J Alzheimers Dis53, 1097–1105.
40.
VidoniED, TownleyRA, HoneaRA, BurnsJM, Alzheimer’s Disease Neuroimaging Initiative (2011) Alzheimer disease biomarkers are associated with body mass index. Neurology77, 1913–1920.
41.
BuchmanAS, SchneiderJA, WilsonRS, BieniasJL, BennettDA (2006) Body mass index in older persons is associated with Alzheimer disease pathology. Neurology67, 1949–1954.
42.
GrundmanM, Corey-BloomJ, JerniganT, ArchibaldS, ThalLJ (1996) Low body weight in Alzheimer’s disease is associated with mesial temporal cortex atrophy. Neurology46, 1585–1591.
43.
EwersM, SchmitzS, HanssonO, WalshC, FitzpatrickA, BennettD, MinthonL, TrojanowskiJQ, ShawLM, FaluyiYO, VellasB, DuboisB, BlennowK, BuergerK, TeipelSJ, WeinerM, HampelH, Alzheimer’s Disease Neuroimaging Initiative (2012) Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer’s disease. Neurobiol Aging33, 1599–1608.
JensenMD, RyanDH, ApovianCM, ArdJD, ComuzzieAG, DonatoKA, HuFB, HubbardVS, JakicicJM, KushnerRF, LoriaCM, MillenBE, NonasCA, Pi-SunyerFX, StevensJ, StevensVJ, WaddenTA, WolfeBM, YanovskiSZ, American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Obesity Society (2014) 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults. J Am Coll Cardiol63, 2985–3023.
53.
MorrisJC, RoeCM, XiongC, FaganAM, GoateAM, HoltzmanDM, MintunMA (2010) APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol67, 122–131.
54.
World Health Organization. Global Database on Body Mass Index.
55.
LiuC-C, ZhaoN, FuY, WangN, LinaresC, TsaiC-W, BuG (2017) ApoE4 accelerates early seeding of amyloid pathology. Neuron96, 1024–1032.e3.
MorminoEC, BetenskyRA, HeddenT, SchultzAP, WardA, HuijbersW, RentzDM, JohnsonKA, SperlingRA, Alzheimer’s Disease Neuroimaging Initiative; Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing; Harvard Aging Brain Study (2014) Amyloid and APOE ɛ4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology82, 1760–1767.
58.
MorminoEC, BetenskyRA, HeddenT, SchultzAP, AmariglioRE, RentzDM, JohnsonKA, SperlingRA (2014) Synergistic effect of β-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol71, 1379.
59.
VosSJB, XiongC, VisserPJ, JasielecMS, HassenstabJ, GrantEA, CairnsNJ, MorrisJC, HoltzmanDM, FaganAM (2013) Preclinical Alzheimer’s disease and its outcome: A longitudinal cohort study. Lancet Neurol12, 957–965.
60.
PetersenRC, WisteHJ, WeigandSD, RoccaWA, RobertsRO, MielkeMM, LoweVJ, KnopmanDS, PankratzVS, MachuldaMM, GedaYE, JackCR (2016) Association of elevated amyloid levels with cognition and biomarkers in cognitively normal people from the community. JAMA Neurol73, 85–92.
61.
BlautzikJ, KotzS, BrendelM, SauerbeckJ, VettermannF, WinterY, BartensteinP, IshiiK, RomingerA (2018) Relationship between body mass index, ApoE4 status, and PET-based amyloid and neurodegeneration markers in amyloid-positive subjects with normal cognition or mild cognitive impairment. J Alzheimers Dis65, 781–791.
62.
FerrettiMT, IulitaMF, CavedoE, ChiesaPA, Schumacher DimechA, Santuccione ChadhaA, BaracchiF, GirouardH, MisochS, GiacobiniE, DepypereH, HampelH, Women’s Brain Project and the Alzheimer Precision Medicine Initiative (2018) Sex differences in Alzheimer disease - the gateway to precision medicine. Nat Rev Neurol14, 457–469.
63.
LawsKR, IrvineK, GaleTM (2018) Sex differences in Alzheimer’s disease. Curr Opin Psychiatry31, 133–139.
64.
KoranMEI, WagenerM, HohmanTJ, Alzheimer’s Neuroimaging Initiative (2017) Sex differences in the association between AD biomarkers and cognitive decline. Brain Imaging Behav11, 205–213.
MazureCM, SwendsenJ (2016) Sex differences in Alzheimer’s disease and other dementias. Lancet Neurol15, 451–452.
67.
AlbaneseE, LaunerLJ, EggerM, PrinceMJ, GiannakopoulosP, WoltersFJ, EganK (2017) Body mass index in midlife and dementia: Systematic review and meta-regression analysis of 589,649 men and women followed in longitudinal studies. Alzheimers Dement (Amst)8, 165–178.
68.
KivipeltoM, NganduT, FratiglioniL, ViitanenM, KåreholtI, WinbladB, HelkalaE-L, TuomilehtoJ, SoininenH, NissinenA (2005) Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol62, 1556–1560.
69.
GustafsonD (2006) Adiposity indices and dementia. Lancet Neurol5, 713–720.
70.
KerwinDR, GaussoinSA, ChlebowskiRT, KullerLH, VitolinsM, CokerLH, KotchenJM, NicklasBJ, Wassertheil-SmollerS, HoffmannRG, EspelandMA (2011) Interaction between body mass index and central adiposity and risk of incident cognitive impairment and dementia: Results from the Women’s Health Initiative Memory Study. J Am Geriatr Soc59, 107–112.
71.
ScarmeasN, LuchsingerJA, BrickmanAM, CosentinoS, SchupfN, Xin-TangM, GuY, SternY (2011) Physical activity and Alzheimer disease course. Am J Geriatr Psychiatry19, 471–481.
